Emerging Infectious Disease Diagnostics Market Forecast Indicates Substantial Expansion Through 2031 Amid Technological Innovations

InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Emerging Infectious Disease Diagnostics Market Size, Share & Trends Analysis Report By Application (Laboratory Testing and Point-of-Care Testing), Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, and Other Technologies), Type of Infection (Bacterial, Viral, Fungal, and Other Infections), Disease Type (Respiratory Infections, Sexually Transmitted Infections (STIs), Gastrointestinal Infections, and Other Infections), End Users (Hospitals and Clinics, Diagnostic Laboratories, and Other End Users) Market Outlook And Industry Analysis 2031"

According to the latest research by InsightAce Analytic, the global Emerging Infectious Disease Diagnostics Market size is valued at US$ 19.23 Bn in 2022, and it is expected to reach US$ 31.76 Bn by the year 2031, recording a promising CAGR of 5.9% during the forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2270

Diagnosing infectious diseases encompasses a range of methodologies and technologies designed to detect and identify pathogenic organisms in individuals suspected of infection. These diagnostic tools facilitate accurate and timely identification, which is critical for improving patient outcomes, reducing morbidity and mortality, and mitigating the spread of infectious diseases.

Molecular diagnostic techniques-such as polymerase chain reaction (PCR), sequencing, and nucleic acid amplification tests (NAATs)-enable the precise detection of pathogens by targeting their genetic material, even in low concentrations. Ongoing research and development initiatives by various companies are focused on enhancing current diagnostic methods and introducing innovative technologies, thereby propelling the growth of the infectious disease diagnostics market.

The COVID-19 pandemic significantly influenced the global landscape of infectious disease diagnostics, leading to a substantial increase in demand for rapid pathogen detection and disease management solutions. This heightened need accelerated the development and deployment of diagnostic capabilities, particularly in point-of-care (POC) testing technologies, which offer faster and more accessible results. As a result, sustained investment and innovation in molecular diagnostic solutions are anticipated to generate substantial growth opportunities in the infectious disease diagnostics market over the coming years.

Some of the prominent players in the Emerging Infectious Disease Diagnostics Market are:
• Abbott Laboratories
• Becton, Dickinson and Company
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Co-Diagnostics, Inc.
• DANAHER CORPORATION
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• T2 Biosystems, Inc.
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Other

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The growth of the emerging infectious disease diagnostics market is being driven by several key factors, including the increasing adoption of point-of-care (PoC) testing systems, the escalating prevalence of infectious diseases, expanding government initiatives and funding for diagnostic development, and ongoing advancements in molecular diagnostic technologies.

Rising Burden of Infectious Diseases:
The global impact of infectious diseases remains substantial, with outbreaks affecting various sectors such as agriculture, manufacturing, supply chains, tourism, and commerce. This widespread disruption has led to a heightened focus on preventive healthcare measures, thereby increasing the demand for effective diagnostic solutions.

Government Support and Funding for Diagnostic Development:
Governments around the world are actively supporting the early detection and monitoring of infectious diseases through targeted funding and policy-driven initiatives. These efforts are aimed at bolstering research and expanding diagnostic capabilities to improve public health outcomes.

Technological Advancements in Molecular Diagnostics:
Ongoing scientific research and development in molecular diagnostics-particularly in areas such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and mass spectrometry-are transforming the diagnostic landscape. These innovations are enhancing the accuracy, speed, and scalability of infectious disease detection, thereby fueling market growth.

Challenges:
Despite the positive outlook, the market faces several challenges, including inadequate reimbursement policies, high costs associated with advanced diagnostic tests, and limited infrastructure to support the widespread adoption of NGS-based technologies. These factors may hinder the broader implementation of emerging diagnostic solutions.

Regional Trends:
North America held the largest share of the emerging infectious disease diagnostics market in 2022. This dominance is attributed to the region's high incidence of infectious diseases, advanced technological infrastructure for diagnostic testing, strong presence of industry players, and proactive government efforts to strengthen healthcare systems. Additionally, an increase in strategic initiatives-such as mergers, acquisitions, research grants, and collaborative ventures-is further contributing to regional market growth.

Key developments in the market:
• In June 2023, T2 Biosystems, Inc. submitted an application to the U.S. Food and Drug Administration (FDA) for breakthrough device designation for the Candida auris Diagnostic test. The company also announced plans to add C. auris detection to its FDA-cleared T2Candida® Panel.
• In April 2023, QIAGEN launched QIAstat-Dx syndromic testing solution in Japan with a respiratory panel for syndromic testing. The SARS-CoV-2 Respiratory Panel can detect more than 20 pathogens from a single patient sample.
• In April 2023, Tecan Trading AG collaborated with DYNEX Technologies to expand the availability of ELISA immunoassays in the U.S.
• In March 2023, QuidelOrtho Corporation received a De Novo Food and Drug Administration (FDA) Authorization for Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance.
• In February 2023, Thermo Fisher Scientific Inc. partnered with Mylab to source RT-PCR test kits for infectious diseases, such as multi-drug resistant tuberculosis (MTB MDR), Hepatitis C virus (HCV), Hepatitis B virus (HBV), Human Immunodeficiency Virus (HIV), genetic analysis (HLA B27), and others.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2270

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Application
• Laboratory Testing
• Point-of-Care Testing
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Technology
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Infection
• Bacterial
• Viral
• Fungal
• Other Infections
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Disease Type
• Respiratory Infections
• Sexually Transmitted Infections (STIs)
• Gastrointestinal Infections
• Other Infections
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on End-Users
• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• U.S.
• Canada
Europe Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/emerging-infectious-disease-diagnostics-market/2270

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.